Pricing
  1. JP-listed companies
  2. BrightPath Biotherapeutics Co., Ltd.
  3. Financials
  4. EBITDA

BrightPath Biotherapeutics Co., Ltd. (4594)

Market cap
¥6.3B
P/E ratio
-5.2x
Brightpath Bio develops novel cancer immunotherapy drugs including cell therapies, antibodies, and personalized vaccines, licensing them to pharmaceutical partners worldwide.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndEBITDA (Million JPY)YoY (%)
Mar 31, 2024-1,155-20.39%
Mar 31, 2023-1,450+0.65%
Mar 31, 2022-1,441-13.52%
Mar 31, 2021-1,666-5.60%
Mar 31, 2020-1,765+11.51%
Mar 31, 2019-1,583+6.33%
Mar 31, 2018-1,489+38.90%
Mar 31, 2017-1,072+10.54%
Mar 31, 2016-969+100.55%
Mar 31, 2015-483

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat